In the current study we have shown that ER-positive/HER2-negative tumours with high-risk recurrence scores had shorter time to develop metastatic disease and shorter overall survival, however we were not able to confirm an association with chemotherapy response. The gene discussed is ERBB2; the disease is neoplasm.